sanofi

\bullet

Stopping a once-daily oral or injectable GLP-1 Receptor Agonist (GLP-1 RA) and starting Toujeo (insulin glargine 300 units/mL)

This presentation has been organised and funded by Sanofi Adverse event reporting and prescribing information is available at the end of this presentation or upon request MAT-XU-2303351 (v2.0) | July 2023

Anne Goodchild Diabetes Specialist Nurse and lead PITstop trainer

Disclaimer

In the last 5 years I have acted as a paid speaker for Napp and Sanofi

I have received payments from Sanofi for delivering PITstop courses to primary care healthcare professionals

sanofi

Structure



- Guidelines & SPS
- Patient Information (case study)
 - Practicalities of starting Toujeo
 - Resources to support (external & Sanofi)

sanofi

Guidelines & Specialist Pharmacy Service Recommendations





medicines advice

Prescribing available insulins

Published 6 July 2023 · Last updated 7 July 2023 · See all updates Topics: Diabetes · Supply

Current supply disruption of GLP-1 receptor agonists means some patients may need to switch to insulin. Prescribers must know which insulins can be used.

www.sps.nhs.uk/articles/prescribing-available-insulins Accessed July 2023

sanofi

Switching from GLP-1 receptor agonists to insulin

Switching from GLP-1 receptor agonists to insulin may be necessary. Recommendations for insulin in this cohort are suggested to ensure supply chains remain stable for the whole population of people with type 1 and type 2 diabetes requiring insulin.

Insulin choice

It is recognised that insulin prescribing is undertaken by healthcare professionals who are competent and confident in insulin initiation and titration, where many factors may influence the decisions to prescribe a particular type of insulin (eq. Basal, Mixed, Intermediate),

The following insulins are currently able to support insulin initiation at the volumes required across the UK as part of the review of patients unable to obtain GLP-1 receptor agonnists. Supply content is maintained by DHSC.

Basal insulin

Able to support switching

First line

· Toujeo 300 units/mL SoloStar, solution for injection

Second line

· Abasaglar 100 units/mL KwikPen solution for injection

Unable to support switching

- · Lantus (insulin glargine) 100 units/mL solution for injection
- · Semglee (insulin glargine) 100 units/mL solution for injection
- · Levemir (insulin detemir) 100 units/mL solution for injection
- Tresiba (insulin degludec) 100 units/mL solution for injection
- Tresiba (insulin degludec) 200 units/mL solution for injection

Intermediate-acting insulin

Able to support switching

· Humulin I KwikPen (insulin isophane) 100 units/mL suspension for injection

Unable to support switching

· Insulatard (insulin isophane) 100 units/mL suspension for injection

Mixed insulin

Able to support switching

Humulin M3 KwikPen (biphasic insulin isophane) 100 units/mL suspension for injection

Unable to support switching

- · Humalog Mix25 (biphasic insulin lispro) 100 units/mL suspension for injection
- · Humalog Mix50 (biphasic insulin lispro) 100 units/mL suspension for injection
- · Novomix 30 (biphasic insulin aspart) 100 units/mL suspension for injection

National guidance regarding GLP-1 RA shortage and use of insulin

Where insulin therapy is clinically indicated, clinicians are advised to initiate insulin in line with principles of NICE NG28.

It is important to note that specific brands of insulin mentioned within NICE NG28 are unlikely to be able to take a large uplift in prescribing, therefore any decisions on insulin brand choice should be based on ongoing insulin availability noted within the SPS supply tool

The choice of insulin should take account of individual characteristics and the clinical needs of the person with T2DM. Where possible, utilise the full range of insulins and devices available to reduce the risk of further impacting supply chain issues.

sanofi

Association of British Clinical Diabetologists	PCDS Primary Care Diabetes Society
Glucagon-Like-Peptide 1 Receptor Ago Guidance from the Primary Care Diabetes Society (PCD Diabetologists (ABCD)	
Authors (listed alphabetically) Hannah Beba ³ , Kevin Cahill, Ketan Dhatariya ³ , Jane Dig Philip Newland Jocoss ² Concul Heavies, Colores ¹ Concul Heavies, Older 4 to Cell Heavies/Local Color Concul Heavies, Older 4 to Cell Heavies/Local Color, PCI Concul Heavies, Older 4 to Cell Heavies/Local Color, PCI Science Heavies Colores and Color SCI Science Heavies and Color SCI Consultation Heavies, Colores 4 Colores and Heavies, Distributes, Heaviers, State Colores and Heaviers, Distributes, Heaviers, State	
Contents	
Title page	
Background	
Scope	
Target audience:	
Advice from the Department of Health & Social Care (I	
Advice for prescribers:	
Clinical review	
Advice for people with T2DM	
Structured education	
Weight management	
Reviewing metabolic response to prescribed GLP-1 RA	
Giving advice when availability of the prescribed GLP-1	
Selecting alternative glucose-lowering therapy when G beneficial metabolic response to GEP-1 RA therapy	LP-1 RAs are unavailable or where there is no
Where insulin therapy is required	
	national shortage has passed


Joint statement from ABCD and PCDS. Glucagon-Like-Peptide 1 Receptor Agonist National Shortage. Guidance from the Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD). <u>https://diabetesonthenet.com/wp-content/uploads/PCDS_ABCD-GLP-1-RA-shortage_20230628.pdf</u> Accessed: July 2023. NICE NG28: <u>Recommendations | Type 2 diabetes in adults: management | Guidance | NICE</u> Accessed: July 2023. SPS supply tool: https://www.sps.nhs.uk/home/tools/medicines-supply-tool Accessed: July 2023.






Selecting alternative glucose-lowering therapy when GLP-1 RAs are unavailable or where there is no beneficial metabolic response to GLP-1 RA therapy

Figure 1. Choosing alternative glucose-lowering therapies in T2DM when GLP-1 RAs are unavailable or there is no beneficial metabolic response.




Note: Symptomatic hyperglycaemia may indicate clinical need for insulin therapy. If in doubt, discuss with specialist. Symptoms of hyperglycaemia include polyuria, polydipsia, weight loss and fatigue. Think 4Ts – Thirst, Toilet, Thinner, Tired.

sanofi



sanofi

© NICE 2022. All rights reserved. Subject to Notice of rights.



5. If adding prandial insulin to NPH, consider initiation of a self-mixed or premixed insulin regimen to decrease the number of injections required

2022;46 (Supplement 1): S140-S157. doi:10.2337/dc23-S009

Case Study



Case study: Stopping a once-daily oral or injectable GLP-1 Receptor Agonist (GLP-1 RA) and starting insulin Toujeo



Grace

• Age 52

Black British ethnic group

- Married with two children in their early twenties, both at home
- Nurse, plus volunteer work some evenings

sanofi

• Duration of diabetes 8 years. Group 1 driver.

• BMI 27.5. Weight 78.5kg. eGFR 69 ml/min/1.73 m 2. Urine ACR 4.1 (CKD G2A2). LFTs normal. No retinopathy, BP in target range

Oral diabetes medication

- Metformin 1g with breakfast, 1g with evening meal
- Canagliflozin 100mg

Additional medications

Losartan 100mg daily and Atorvastatin 20mg daily

Treatment Year	liraglutide dose	Pts HbA1c (mmol/mol)	Pts Weight (kg)
2015		68	89
2018	$0.6mg \rightarrow 1.2mg$	$82 \to 75 \to 69$	80
2019 -22	1.2mg Canagliflozin added 2021	$\begin{array}{c} 76 \rightarrow 67 \rightarrow 60 \\ 56 \rightarrow 50 \end{array}$	83 79
2023	1.2mg	53	78.5

Treatment Options

Option 1:

Discuss with Grace that intermittent supply of their GLP-1 RA may be associated with increased side effects and erratic blood glucose control, with potential to increase diabetes- related complications.

Option 2:

- Consider optimising Grace's current oral glucose lowering medications
- Once doses optimised, consider adding an additional oral glucose lowering therapy as per NICE NG28
- For people established on maximum oral dose(s) consider starting insulin
- Plan follow-up as clinically appropriate

sanofi

Joint statement from ABCD and PCDS. Glucagon-Like-Peptide 1 Receptor Agonist National Shortage. Guidance from the Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD). <u>https://diabetesonthenet.com/wp-content/uploads/PCDS_ABCD-GLP-1-RA-shortage_20230628.pdf</u> Accessed: July 2023.

Important to consider

Grace's HbA1c and weight trajectory. She has responded well on her current treatment regimen and will be reluctant to stop liraglutide

Her 8-year duration of diabetes (importance of maintaining tight glycaemic control around 53mmol/mol - already known to have microalbuminuria). Wise to escalate treatment rather than rely on intermittent supply of GLP-RA Concordance with current oral medications. Could simplify and escalate doses

The way she currently lives her life

Not currently monitoring her blood glucose due to current regimen


Check the current Out of Stock information and advice on SPS website

 Joint statement from ABCD and PCDS. Glucagon-Like-Peptide 1 Receptor Agonist National Shortage. Guidance from the Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD). <u>https://diabetesonthenet.com/wp-content/uploads/PCDS_ABCD-GLP-1-RA-shortage_20230628.pdf</u> Accessed: July 2023.

2. www.sps.nhs.uk/articles/prescribing-available-insulins/ Accessed: July 2023

sanofi

Timeline: "Talk me through a normal working day"



sanofi

Optimise doses of current oral meds and consider additional medications relevant to the individual

- 1. Would like current medication to be once daily **Solution:** discuss use of modified-release Metformin 1g tablets taken together
- 2. Use the medication in class with best efficacy for HbA1c and weight reduction **Solution:** increase Canagliflozin to 300mg (eGFR > 60mL/min/1.73m2)
- 3. Adding additional oral medication
 - Pioglitazone discussed. Not keen due to increased fracture risk
 - DPP-4 inhibitor. Been on one before with little glycaemic improvement
 - Sulfonylurea. Tried before and problems with hypoglycaemia due to erratic eating
 - Repaglinide is an option before high carbohydrate meals only
- 4. Start basal insulin
 - Humulin I and Toujeo available options. Varied lifestyle and no set bedtime so preferred Toujeo with the three-hour window either side of the injection time when needed
 - The recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments. The dose regimen (dose and timing) should be adjusted according to individual response
 - START TOUJEO SOLOSTAR ONE DAY AFTER DISCONTINUING THE DAILY GLP-1 RA

Joint statement from ABCD and PCDS. Glucagon-Like-Peptide 1 Receptor Agonist National Shortage. Guidance from the Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD). <u>https://diabetesonthenet.com/wp-content/uploads/PCDS_ABCD-GLP-1-RA-shortage_20230628.pdf</u> Accessed: July 2023.

sanofi

Zaccardi F. et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis Diabetes, Obesity and Metabolism, 2016;18:783–794.

Oral agents and insulin

NICE¹

- Continue to offer metformin (if no contraindications or intolerance).
- Review the continued need for other blood glucose lowering therapies (an SGLT-2i in combination with insulin is an option)

Stop medicines that have had no impact on glycaemic control or weight, unless there is an additional clinical benefit, such as cardiovascular or renal protection, from continued treatment

ADA / EASD²

sanofi

- Add basal insulin to existing pharmacological therapies
- Agents that cause hypoglycaemia in themselves, such as Sulfonylureas, should be **discontinued**
 - 1. NICE (2015, updated June 2022) NG28, *Type 2 Diabetes in adults: management www.nice.org.uk/Guidance/NG28* Accessed: July 2023.

 Davies M.J., Aroda V.R., Collins B.S et al. Management of Hyperglycaemia in Type 2 Diabetes, 2022. A consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, Sept 2022, https://doi.org/10.1007/s00125-022-05787-2 Accessed: July 2023.

Starting Toujeo





Initiation of Toujeo



Toujeo is a basal insulin for once-daily administration at any time of the day, preferably at the same time every day



The dose regimen (dose and timing) should be adjusted according to individual response



In patients with type 2 diabetes mellitus, Toujeo can also be given together with other anti-hyperglycaemic medicinal products




The recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments



Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia

Starting Toujeo SoloStar: resources to help

Toujeo SoloStar Handbook



SoloStar	Insulin	Passport

Toujeo* 300 within SoloStar advance for instance advance for instance for instance advance for instance f	I have diabetes and use Toujeo® SoloStar® (insulin glargine 300 units/mL)	
insulin pla&Bore gan relative table prote to generate sources san relative table prote to generate sources sources and sources and sources and sources and sources and sources and source	Other Insulins:	
Couper meters and a second sec	Other Medication:	
Name:		
	Reporting of side effects	
Date of birth:	Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side	
NHS Number:	effects not listed in the package leaflet. You can also report side effects directly: In the UK, via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. In Ireland, at www.hpra.ie; email medsafety@hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.	
Emergency Contact:	Sanofi Medical Information Line Freephone 08000 35 25 25	
	If your insulin prescription is changed, please destroy this card and collect a replacement.	
sanofi	Date of preparation: May 2022 This Item is intended for patients. MAT:XU-2200796(v1.0)	

- 1. Patient resources: https://www.mysanofiinsulin.co.uk/home/ Accessed: July 2023.
- 2. Healthcare professional education and resources <u>https://www.campus.sanofi/uk/products/diabetes/toujeo</u> Accessed: July 2023.
- **SONOFI** 3. Get in touch for details of your local Sanofi representative or to order patient literature or dummy devices <u>https://www.campus.sanofi/uk/science/get-in-touch</u> Accessed: July 2023.



Notifying the DVLA - Patients will need to be taught blood glucose monitoring

Treatment	Group 1	Group 2
Diabetes managed by diet / lifestyle	X	X
Managed by medication not associated with hypoglycaemia (Metformin, Pioglitazone, DPP-4i, SGLT-2i, GLP-1 RA)	X	\checkmark
Managed by tablets causing a hypoglycaemia risk (Sulphonylureas and Glinides)	x	\checkmark
Diabetes treatment with insulin	\checkmark	\checkmark

sanofi

X

No need to notify providing there are no other disqualifying complications (e.g. vision, sensation, circulation)

Resources available for Health Care Professionals and Patients



Resources to support starting insulin



Programme for injectable therapy for type 2 diabetes, 10th edition. A guide for patients during the assessment stage and the initial 6-months follow-up and other useful resources





 Trend Diabetes Injection Technique Matters resources <u>https://trenddiabetes.online/injection-technique-matters/</u> Accessed: July 2023.
<u>https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/insulin</u> https://diabetesonthenet.com/ Accessed July 2023

Resources to help discuss her timeline and agree a lifestyle goal and action plan



do this **Kickstart your health** Healthy changes start with little changes. Whether you want to lose weight, get active or guilt smoking, Better Health is here with lats of free tools and support. You can also find simple ways to lift your mood with There has never been a better time to kickstart your health. Let's do this Get active Losing weight is not about getting it right - it's about getting started. Making small, simple changes can really help you shed No matter how active you are physical activity is good for your body and mind. Aim to be active every day, the more you the pounds Get started today with our do the better you'll feel. Try these tools tins, support and spacial offers tips and special offers to get active and Quit smoking Drink less Smoking weakens our lungs and makes it harder to breathe. Check out the free Drinking less can help you feel a bit bette every day - and it's easier to make a change than you think. We have some tools and tips available and join millions who have successfully quit smoking simple tips and tools to help you star cutting down today Take care of your mind ing after your mind is just as important oking after your body, but it can be ear





Carbs & Cals website, books and App

SGNOFI NHS Better Health website, including access to the Active 10 App <u>https://www.nhs.uk/better-health/</u> Accessed July 2023 NHS Every Mind Matters website <u>https://www.nhs.uk/every-mind-matters/</u> Accessed July 2023

ical tips to help you stay on top of you


NHS England digital weight loss Programme

12-week programme Requires a practice or pharmacy referral

Who can be referred to the programme?

- Over 18
- BMI 30 or more (≥ 27.5 for people from black, Asian, and ethnic minority backgrounds)
- Have diabetes (type 1 or type 2), high blood pressure, or both.
- Have a smartphone, tablet, or computer with internet access

Excluded: moderate/severe frailty, pregnant, eating disorder, bariatric surgery in last 2 years



Sanofi www.england.nhs.uk/digital-weight-management/how-to-access-the-programme/ Accessed July 2023

Prescribing Information: Toujeo® (insulin glargine 300 units/ml)

Please refer to Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Toujeo SoloStar pre-filled pens each ml contains 300 units of insulin glargine. SoloStar pen contains 1.5ml (450 units) of solution for injection. DoubleStar pen contains 3ml (900 units) of solution for injection.

Indication: Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. Dosage and Administration: Toujeo is administered

subcutaneously, by injection into the abdominal wall, the deltoid or the thigh, once daily, at any time of the day, preferably at the same time every day. The dose regimen (dose and timing) should be adjusted according to individual response. Injection sites must be rotated within a given injection area from one injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis. Do not administer intravenously. In type 1 diabetes mellitus, Toujeo must be combined with short-/rapidacting insulin to cover mealtime insulin requirements. In patients with type 2 diabetes mellitus. recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments. Toujeo can also be given together with other anti-hyperglycaemic medicinal products. Switch between insulin glargine 100 units/ml and Toujeo: Insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not directly interchangeable. When switching from insulin glargine 100 units/ml to Toujeo, this can be done on a unit-to-unit basis, but a higher Toujeo dose (approximately 10-18%) may be needed to achieve target ranges for plasma glucose levels. When switching from Toujeo to insulin glargine 100 units/ml, the dose should be reduced (approximately by 20%). Switching from other basal insulins to Toujeo: A change of dose and/or timing of the basal insulin and concomitant anti-hyperglycaemic treatment may be required. Dose adjustments may also be required if the patient's weight or lifestyle changes, the timing of insulin dose is changed or other circumstances arise that increase susceptibility to hypo- or hyperglycaemia. Toujeo must not be mixed or diluted with any other insulin or other medicinal products. Close metabolic monitoring is recommended during a switch and in the initial weeks thereafter. SoloStar 1-80 units per single injection in steps of 1 unit and DoubleStar 2-160 units in steps of 2 units. When changing from Toujeo SoloStar to Toujeo DoubleStar, if the patient's previous dose was an odd number then the dose must be increased or decreased by 1 unit. Toujeo DoubleStar prefilled pen is recommended for patients requiring at least 20 units per day. Special Populations: Elderly, renal and hepatic impairment: Insulin requirements may be diminished in the elderly or patients with renal or hepatic impairment. Paediatric: When switching basal insulin to Toujeo, dose reduction of basal and bolus insulin needs to be considered on an individual basis, in order to minimise the risk of hypoglycaemia.

Contraindications: Hypersensitivity to insulin glargine or any excipients.

Precautions and Warnings: <u>Traceability</u>: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Toujeo is not the insulin of choice for treatment of diabetic ketoacidosis. Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose

sanofi

monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered. Hypoglycaemia: In case of insufficient glucose control or a tendency to hyper/hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. Particular caution should be exercised, and intensified blood glucose monitoring is advisable for patients in whom hypoglycaemic episodes might be of clinical relevance and in those where dose adjustments may be required. Warning signs of hypoglycaemia may be changed, less pronounced or absent in certain risk groups, potentially resulting in severe hypoglycaemia and loss of consciousness. Risk groups include patients in whom glycaemic control is markedly improved, hypoglycaemia develops gradually, an autonomic neuropathy is present, or who are elderly. The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia. Intercurrent illness: Requires intensified metabolic monitoring and often it is necessary to adjust the insulin dose. Insulin antibodies: administration may cause insulin antibodies to form. Use with pioglitazone: Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs. Medication errors: Insulin labels must always be checked before each injection to avoid errors between Toujeo and other insulins. Patients must be instructed to never use a syringe to remove Toujeo from the SoloStar or DoubleStar pre- filled pen, A new sterile needle must be attached before each injection. Needles must not be re-used. Pregnancy and breast- feeding: There is no data from exposed pregnancies in controlled clinical trials. However, there is a large amount of data on use of insulin glargine 100 units/ml in pregnant women indicating no specific adverse effects on pregnancy and no specific malformative nor feto/neonatal toxicity. The use of Toujeo may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. It is unknown if insulin glargine is excreted in breast milk. Interactions: Substances that affect glucose metabolism may require adjustment of insulin glargine.

Adverse Reactions: <u>Very common</u>: Hypoglycaemia. Prolonged or severe hypoglycaemia may be lifethreatening. <u>Common</u>: Lipohypertrophy, injection site reactions, including redness, pain, itching, hives, swelling, or inflammation. <u>Not known</u>: Cutaneous amyloidosis. Prescribers should consult the SmPC in relation to other adverse reactions.

GB List Price: SoloStar 3 x 1.5ml pens: £32.14; DoubleStar 3 x 3ml pens: £64.27

Legal Category: POM Marketing Authorisation Number: SoloStar 3 Pen pack: PLGB 04425/0817; DoubleStar 3 Pen pack: PLGB 04425/0818. Marketing Authorisation Holder: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Further information is available from: Medical Information, Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. <u>ukmedicalinformation@sanofi.com</u>.

Date of Preparation: September 2022

Adverse events should be reported. Reporting forms and information can be found at <u>www.mhra.gov.uk/yellowcard</u> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314. Alternatively, send via email to UK- drugsafety@sanofi.com

Please refer to Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Toujeo SoloStar pre-filled pens each ml contains 300 units of insulin glargine. SoloStar pen contains 1.5ml (450 units) of solution for injection. DoubleStar pen contains 3ml (900 units) of solution for injection.

Indication: Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. Dosage and Administration: Toujeo is administered

subcutaneously, by injection into the abdominal wall, the deltoid or the thigh, once daily, at any time of the day, preferably at the same time every day. The dose regimen (dose and timing) should be adjusted according to individual response. Injection sites must be rotated within a given injection area from one injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis. Do not administer intravenously. In type 1 diabetes mellitus, Toujeo must be combined with short-/rapidacting insulin to cover mealtime insulin requirements. In patients with type 2 diabetes mellitus, recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments. Toujeo can also be given together with other anti-hyperglycaemic medicinal products. Switch between insulin glargine 100 units/ml and Toujeo: Insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not directly interchangeable. When switching from insulin glargine 100 units/ml to Toujeo, this can be done on a unit-to-unit basis, but a higher Toujeo dose (approximately 10-18%) may be needed to achieve target ranges for plasma glucose levels. When switching from Toujeo to insulin glargine 100 units/ml, the dose should be reduced (approximately by 20%). Switching from other basal insulins to Toujeo: A change of dose and/or timing of the basal insulin and concomitant anti-hyperglycaemic treatment may be required. Dose adjustments may also be required if the patient's weight or lifestyle changes, the timing of insulin dose is changed or other circumstances arise that increase susceptibility to hypo- or hyperglycaemia. Touleo must not be mixed or diluted with any other insulin or other medicinal products. Close metabolic monitoring is recommended during a switch and in the initial weeks thereafter. SoloStar 1-80 units per single injection in steps of 1 unit and DoubleStar 2-160 units in steps of 2 units. When changing from Toujeo SoloStar to Toujeo DoubleStar, if the patient's previous dose was an odd number then the dose must be increased or decreased by 1 unit. Toujeo DoubleStar prefilled pen is recommended for patients requiring at least 20 units per day. Special **Populations:** Elderly, renal and hepatic impairment: Insulin requirements may be diminished in the elderly or patients with renal or hepatic impairment. Paediatric: When switching basal insulin to Toujeo, dose reduction of basal and bolus insulin needs to be considered on an individual basis, in order to minimise the risk of hypoglycaemia.

Contraindications: Hypersensitivity to insulin glargine or any excipients.

sanofi

Precautions and Warnings: <u>Traceability</u>: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Toujeo is not the insulin of choice for treatment of diabetic ketoacidosis. Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site,

and dose adjustment of antidiabetic medications may be considered. Hypodlycaemia: In case of insufficient glucose control or a tendency to hyper/hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. Particular caution should be exercised, and intensified blood glucose monitoring is advisable for patients in whom hypoglycaemic episodes might be of clinical relevance and in those where dose adjustments may be required. Warning signs of hypoglycaemia may be changed, less pronounced or absent in certain risk groups, potentially resulting in severe hypoglycaemia and loss of consciousness. Risk groups include patients in whom glycaemic control is markedly improved, hypoglycaemia develops gradually, an autonomic neuropathy is present, or who are elderly. The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia. Intercurrent illness: Requires intensified metabolic monitoring and often it is necessary to adjust the insulin dose. Insulin antibodies: administration may cause insulin antibodies to form. Use with pioglitazone: Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs. Medication errors: Insulin labels must always be checked before each injection to avoid errors between Toujeo and other insulins. Patients must be instructed to never use a syringe to remove Toujeo from the SoloStar or DoubleStar pre- filled pen, A new sterile needle must be attached before each injection. Needles must not be re-used. Pregnancy and breast-feeding: There is no data from exposed pregnancies in controlled clinical trials. However, there is a large amount of data on use of insulin glargine 100 units/ml in pregnant women indicating no specific adverse effects on pregnancy and no specific malformative nor feto/neonatal toxicity. The use of Toujeo may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. It is unknown if insulin glargine is excreted in breast milk. Interactions: Substances that affect glucose metabolism may require adjustment of insulin glargine. Adverse Reactions: Very common: Hypoglycaemia. Prolonged or severe hypoglycaemia may be lifethreatening. Common: Lipohypertrophy, injection site reactions, including redness, pain, itching, hives, swelling, or inflammation. Not known: Cutaneous amyloidosis. Prescribers should consult the SmPC in relation to other adverse reactions.

NI List Price: SoloStar 5 x 1.5ml pens: £53.57; DoubleStar 3 x 3ml pens: £64.27.

Legal Category: POM Marketing Authorisation Number: SoloStar 5 Pen pack: EU/1/00/133/035; DoubleStar 3 Pen pack: EU/1/00/133/038. Marketing Authorisation Holder: Sanofi Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany. Further information is available from: Medical Information, Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. <u>uk-</u> medicalInformation@sanofi.com.

Date of Preparation: September 2022

Adverse events should be reported. Reporting forms and information can be found at <u>www.mhra.gov.uk/yellowcard</u> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314. Alternatively, send via email to <u>UK- drugsafety@sanofi.com</u>